SPC508
daratumumab, bortezomib, lenalidomide and dexamethasone
Status:
UmsóknApplication date:
16.4.2025Application published:
1.5.2025
Medicine name:
DARZALEXMedicine for children:
No
Timeline
Today
16.4.2025Application
1.5.2025Publication
Marketing license
IS authorization number:
EU/1/16/1101Date:
14.1.2022
Foreign authorization number:
EU/1/16/1101Date:
21.10.2024
Owner
Name:
Genmab A/SAddress:
Carl Jacobsens Vej 30, Valby DK
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128 Reykjavík
Patent
Number:
EP2081595
Deadlines
TypeDeadline until
Type: Formgallafrestur, fyrsti
Deadline until: 07.08.2025